Evolution and impact of ventricular assist device program on children awaiting heart transplantation

Iki Adachi1, Muhammad S Khan2, Francisco A Guzmán-Pruneda1

  • 1Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas; Congenital Heart Surgery, Texas Children's Hospital, Houston, Texas.

Insights

The evolution of pediatric mechanical circulatory support (MCS) programs has significantly improved heart transplant outcomes. Increased use of long-term MCS devices reduced wait-list mortality and enhanced survival rates in children awaiting transplants.

Area of Science:

  • Pediatric Cardiology
  • Transplant Surgery
  • Biomedical Engineering

Background:

  • Mechanical circulatory support (MCS) programs have evolved significantly.
  • The impact of these program changes on pediatric heart transplantation outcomes requires evaluation.

Purpose of the Study:

  • To assess how advancements in a pediatric mechanical circulatory support (MCS) program influenced outcomes for children listed for heart transplantation.
  • To compare pre- and post-2005 outcomes, after the institution could provide long-term MCS without size limitations.

Main Methods:

  • A retrospective review of pediatric patients listed for isolated heart transplantation between 1995 and 2013.
  • Analysis of wait-list and post-transplant outcomes, comparing data from before and after 2005.
  • Recording the utilization of MCS during the wait-list period.

Main Results:

  • The utilization of MCS increased significantly from 13% to 37% between the study eras.
  • Wait-list mortality decreased substantially from 25% to 11%.
  • Survival rates at 1 and 5 years post-transplant showed an improving trend (70% vs. 88% at 1 year; 60% vs. 78% at 5 years).

Conclusions:

  • Pediatric heart transplantation outcomes have markedly improved over two decades.
  • Maturation of MCS strategies, emphasizing long-term devices over temporary ones like ECMO, is a key factor in these improved outcomes.
  • Aggressive use of advanced long-term MCS devices has positively impacted bridge-to-transplant success.
Abstract

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
724
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
614
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
811